Abbott (NYSE:ABT) reportedly stopped selling its Xience Alpine drug-eluting coronary stent in India this week in response to price caps set by the National Pharmaceutical Pricing Authority.
A spokesperson for the healthcare firm said in a statement that Abbott “fulfilled all the requirements to discontinue selling its Xience Alpine drug-eluting stent in India as of April 26,” according to Business Standard.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott pulls Xience Alpine drug-eluting stent from Indian market appeared first on MassDevice.